Directorio de personas
Nuria Eritja Sanchez

Nuria Eritja Sanchez

Grado: Doctor/a

973 70 29 37
neritja(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/I-3790-2017

Grupos

Publicaciones

  • Tellez-Quijorna, C; Juan-Lopez, A; Eritja, N; Llobet-Navas, D; Devis-Jauregui, L

    Dysregulated autophagy in endometriosis: molecular mechanisms, controversies, and clinical implications

    Reproductive Biology and Endocrinology 24 -. .

    [doi:10.1186/s12958-025-01494-w]

  • Gatius, S; Vaquero, M; Scheiber, O; Velasco, A; Cuevas, D; Kashofer, K; Santacana, M; Eritja, N; Lax, S; Matias-Guiu, X

    EPM2 AIP1 immunohistochemistry as a surrogate of promoter methylation analysis in endometrial carcinoma

    VIRCHOWS ARCHIV 487 511-522. .

    [doi:10.1007/s00428-025-04132-3]

  • de la Rosa, I; Sisó, P; Ríos, C; Gracia, J; Cuevas, D; Maiques, O; Eritja, N; Soria, X; Angel-Baldó, J; Gatius, S; Sanchez-Moral, L; Sarrias, MR; Matias-Guiu, X; Martí, RM; Macià, A

    High Copy Number Variations Correlate with a Pro-Tumoral Microenvironment and Worse Prognosis in Acral Lentiginous Melanoma

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 26 -. .

    [doi:10.3390/ijms26094097]

  • Rodríguez-Martínez, A; Torrejón-Escribano, B; Eritja, N; Dorca-Arévalo, J; Gabaldón, C; Sévigny, J; Matias-Guiu, X; Martín-Satué, M

    Endometrial epithelial cell organoids as tools for studying the CD39 family of enzymes and for validating enzyme inhibitors

    HISTOLOGY AND HISTOPATHOLOGY 40 171-182. .

    [doi:10.14670/HH-18-782]

  • Alberti-Valls, M; Olave, S; Olomí, A; Macià, A; Eritja, N

    Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment

    Cancers 16 -. .

    [doi:10.3390/cancers16233918]

  • Albertí-Valls M; Megino-Luque C; Macià A; Gatius S; Matias-Guiu X; Eritja N

    Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review.

    Cancers 16 -. .

    [doi:10.3390/cancers16010185]

  • Sonzini, G; Granados-Aparici, S; Sanegre, S; Diaz-Lagares, A; Diaz-Martin, J; de Andrea, C; Eritja, N; Bao-Caamano, A; Costa-Fraga, N; García-Ros, D; Salguero-Aranda, C; Davidson, B; López-López, R; Melero, I; Navarro, S; Ramon Y Cajal, Santiago; de Alava, E; Matias-Guiu, X; Noguera, R

    Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness.

    Frontiers In Cell And Developmental Biology 10 1052098-1052098. .

    [doi:10.3389/fcell.2022.1052098]

  • Barceló, C; Sisó, P; de la Rosa, I; Megino-Luque, C; Navaridas, R; Maiques, O; Urdanibia, I; Eritja, N; Soria, X; Potrony, M; Calbet-Llopart, N; Puig, S; Matías-Guiu, X; Martí, RM; Macià, A

    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.

    BRITISH JOURNAL OF CANCER 127 1142-1152. .

    [doi:10.1038/s41416-022-01886-4]

  • Ruiz-Mitjana, A; Navaridas, R; Vidal-Sabanés, M; Perramon-Güell, A; Yeramian, A; Felip, I; Eritja, N; Egea, J; Encinas, M; Matias-Guiu, X; Dolcet, X

    Lack of extracellular matrix switches TGF-ß induced apoptosis of endometrial cells to epithelial to mesenchymal transition.

    SCIENTIFIC REPORTS 12 14821-14821. .

    [doi:10.1038/s41598-022-18976-1]

  • Gatius S; Jove M; Megino-Luque C; Albertí-Valls M; Yeramian A; Bonifaci N; Piñol M; Santacana M; Pradas I; Llobet-Navas D; Pamplona R; Matías-Guiu X; Eritja N

    Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

    Cancers 14 -. .

    [doi:10.3390/cancers14122842]

  • Megino-Luque, C; Sisó, P; Mota-Martorell, N; Navaridas, R; de la Rosa I; Urdanibia, I; Alberti-Valls, M; Santacana, M; Pinyol, M; Bonifaci, N; Macià, A; Llobet-Navas, D; Gatius, S; Matias-Guiu, X; Eritja, N

    ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.

    MOLECULAR ONCOLOGY 16 2235-2259. .

    [doi:10.1002/1878-0261.13193]

  • Eritja N; Navaridas R; Ruiz-Mitjana A; Vidal-Sabanés M; Egea J; Encinas M; Matias-Guiu X; Dolcet X

    Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

    Cancers 13 -. .

    [doi:10.3390/cancers13194990]

Proyectos

  • Unravelling the molecular and phenotypic complexity of endometriosis through new models and omics integration: towards a personalized clinical management
  • Targeted design of edible nanostructured delivery systems containing beta-carotene as a diet supplementation strategy with antitumoral activity
  • Implicación de ARID1A en la remodelación del microambiente tumoral y la reprogramación metabólica en el cáncer endometrial
  • Papel de ARID1A en la carcinogénesis endometrial dependiente de contexto. Análisis de los mecanismos moleculares y posibles implicaciones terapéuticas
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • Contrato Miguel Servet - Proyecto
  • Contrato Miguel Servet - RRHH
  • LYOTEK
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • "Determinación del perfil metabólico del carcinoma endometrioide de endometrio grado 3 para discriminar los subtipos tumorales establecidos por clasificación del TCGA (The Cancer Genome Atlas Research Network)"
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI